These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. More on the use of bisphosphonates in the prevention and treatment of osteoporosis. Minisola S; Cipriani C; Scillitani A; Pepe J BMJ; 2015 Nov; 351():h5868. PubMed ID: 26538380 [No Abstract] [Full Text] [Related]
23. Bisphosphonates and the Role of Calcium Plus Vitamin D in Osteoporosis. Comito RR; Richard K Conn Med; 2017 May; 81(5):299-305. PubMed ID: 29738132 [No Abstract] [Full Text] [Related]
25. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros. Rossini M; Orsolini G; Viapiana O; Adami S; Gatti D Endocrine; 2015 Aug; 49(3):620-7. PubMed ID: 25649760 [TBL] [Abstract][Full Text] [Related]
26. Treatment of osteoporosis in women intolerant of oral bisphosphonates. Aspray TJ; Francis RM Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368 [TBL] [Abstract][Full Text] [Related]
27. Transient osteoporosis of the hip: review of the literature. Asadipooya K; Graves L; Greene LW Osteoporos Int; 2017 Jun; 28(6):1805-1816. PubMed ID: 28314897 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia. Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349 [TBL] [Abstract][Full Text] [Related]
29. Transient osteoporosis of the hip in association with osteogenesis imperfecta: two cases, one complicated by a femoral neck fracture. Young SD; Nelson CL; Steinberg ME Am J Orthop (Belle Mead NJ); 2008 Feb; 37(2):88-91. PubMed ID: 18401484 [No Abstract] [Full Text] [Related]
31. Bisphosphonates for osteoporosis in people with cystic fibrosis. Conwell LS; Chang AB Cochrane Database Syst Rev; 2009 Oct; (4):CD002010. PubMed ID: 19821288 [TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Ito K; Blinder VS; Elkin EB J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313 [TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates in General Practice: An Audit on the Management of Osteoporosis. Akintola A; Sidky S Ir Med J; 2017 Oct; 110(9):642. PubMed ID: 29372957 [No Abstract] [Full Text] [Related]
34. Bisphosphonates, Bone and Joint Pain. Villatoro-Villar M; Kwoh CK Curr Osteoporos Rep; 2021 Aug; 19(4):417-428. PubMed ID: 34215993 [TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates for the prevention and treatment of osteoporosis. Maraka S; Kennel KA BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528 [TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates and osteoporosis: which therapeutic agent is best? Bannon M QJM; 2011 Apr; 104(4):279-80. PubMed ID: 21421549 [No Abstract] [Full Text] [Related]
37. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). Sanders J; Crawford B; Gibson J; Joy Ho P; Iland H; Joshua D Int J Lab Hematol; 2007 Oct; 29(5):395-7. PubMed ID: 17824924 [No Abstract] [Full Text] [Related]
38. [Bisphosphonates in osteoporosis therapy. Standards and perspectives]. Reinsdorf S; Habermann B; Hochmuth K; Kurth AA Orthopade; 2007 Feb; 36(2):110-7. PubMed ID: 17252258 [TBL] [Abstract][Full Text] [Related]
39. Osteoporosis treatment may benefit breast cancer patients. Kremer R Womens Health (Lond); 2015 Nov; 11(6):789-92. PubMed ID: 26541855 [No Abstract] [Full Text] [Related]